Cancer name Epithelial Ovarian Carcinoma
Cancer Type OV
Immunotherapy type Cancer Vaccine
Treatment AMHR2-ED (anti-Müllerian hormone receptor II)
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Gene
Signature Bax
Official Symbol BAX
Mode of action TRAN_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description In addition, qRT-PCR analysis showed that the increased frequencies of apoptotic tumor cells in AMHR2-ED vaccinated mice occurred in the presence of sig-nificantly increased expression of the proapoptotic Bax gene compared with EOC from control vaccinated mice.
PMID 29093011
Title Primary Immunoprevention of Epithelial Ovarian Carcinoma by Vaccination against the Extracellular Domain of Anti-Müllerian Hormone Receptor II